clinical trial · NCT00989469
Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
Institut du Cancer de Montpellier - Val d'Aurelle·phase2·completed·n = 64
Metastatic Colorectal CancerNexavar (Sorafenib) and irinotecan (Campto)
brief summary
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.
started
Feb 1, 2009
primary completion
Feb 1, 2011
completion
Feb 1, 2012
last updated
Feb 5, 2026
official title
SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol